JP2017522886A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522886A5
JP2017522886A5 JP2017504353A JP2017504353A JP2017522886A5 JP 2017522886 A5 JP2017522886 A5 JP 2017522886A5 JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017522886 A5 JP2017522886 A5 JP 2017522886A5
Authority
JP
Japan
Prior art keywords
antibody
seq
htt
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522886A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/067327 external-priority patent/WO2016016278A2/en
Publication of JP2017522886A publication Critical patent/JP2017522886A/ja
Publication of JP2017522886A5 publication Critical patent/JP2017522886A5/ja
Pending legal-status Critical Current

Links

JP2017504353A 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン(htt)抗体及びその使用 Pending JP2017522886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179004.8 2014-07-29
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096056A Division JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2017522886A JP2017522886A (ja) 2017-08-17
JP2017522886A5 true JP2017522886A5 (enExample) 2018-10-18

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504353A Pending JP2017522886A (ja) 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン(htt)抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン(htt)抗体及びその使用

Country Status (11)

Country Link
US (3) US10556946B2 (enExample)
EP (2) EP3174898A2 (enExample)
JP (3) JP2017522886A (enExample)
KR (1) KR102643395B1 (enExample)
CN (2) CN113651887A (enExample)
AU (3) AU2015295441B2 (enExample)
CA (1) CA2954738A1 (enExample)
EA (1) EA201790165A1 (enExample)
IL (2) IL250180A0 (enExample)
MX (3) MX391037B (enExample)
WO (1) WO2016016278A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EA201790165A1 (ru) * 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
EP4233901A3 (en) 2017-08-22 2023-09-06 Biogen MA Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates
TW202110878A (zh) * 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
AU2020363372A1 (en) 2019-10-07 2022-05-19 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
WO2021151079A1 (en) 2020-01-24 2021-07-29 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
KR102549520B1 (ko) 2021-01-29 2023-07-03 일리미스테라퓨틱스 주식회사 비염증성 식세포작용 유도 활성을 갖는 융합분자
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
EP4630449A1 (en) * 2022-12-07 2025-10-15 Alchemab Therapeutics Ltd. Anti-huntingtin antibodies

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
JPH02503867A (ja) 1988-04-15 1990-11-15 プロテイン デザイン ラブズ インコーポレーテッド Il‐2レセプター特異的キメラ抗体
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ES2178635T3 (es) 1990-11-09 2003-01-01 Stephen D Gillies Inmunoconjugados de citoquinas.
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
PL191251B1 (pl) 1997-03-14 2006-04-28 Idec Pharma Corp Sposób wprowadzania żądanego DNA w docelowe miejsce w genomie ssaka i układ wektorów
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1999006838A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel method of detecting amyloid-like fibrils or protein aggregates
AU1631700A (en) 1998-11-23 2000-06-13 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
JP4368196B2 (ja) 2000-11-17 2009-11-18 ユニバーシティー オブ ロチェスター 真核細胞において免疫グロブリン分子を製造および同定するインビトロにおける方法
EP1373321A2 (en) 2001-01-29 2004-01-02 Idec Pharmaceuticals Corporation Modified antibodies and methods of use
WO2002096948A2 (en) 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP2319936A3 (en) * 2001-02-15 2012-10-17 The University of Chicago Yeast screens for agents affecting protein folding
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7375194B2 (en) * 2002-01-28 2008-05-20 California Institute Of Technology Antibodies that bind to an epitope on the Huntington's disease protein
AU2004239114B2 (en) * 2003-05-14 2008-03-13 Japan Science And Technology Agency Inhibition of the expression of huntingtin gene
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
EP2099826B1 (en) 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid antibody and uses thereof
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
EP2651979B1 (en) 2010-12-17 2019-08-28 Neurimmune Holding AG Human anti-sod1 antibodies
EP2678026B1 (en) 2011-02-21 2016-05-18 The University of Zurich Ankyrin g for use in the treatment of neurodegenerative disorders
WO2013013025A2 (en) * 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
EP3964524A1 (en) 2011-10-28 2022-03-09 Biogen International Neuroscience GmbH Tdp-43 specific binding molecules
CN111205369B (zh) * 2013-05-29 2024-03-08 维拜昂公司 改变亨廷顿蛋白突变体降解的单链胞内抗体
CA2954687A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
CN106687475A (zh) * 2014-07-10 2017-05-17 阿费里斯股份公司 用于预防和/或治疗亨廷顿氏病的物质和方法
EA201790165A1 (ru) * 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение

Similar Documents

Publication Publication Date Title
JP2017522886A5 (enExample)
US11685776B2 (en) Engineered heterodimeric proteins
JP2012501670A5 (enExample)
JP2013535191A5 (enExample)
FI3826667T3 (fi) Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi
RU2012112340A (ru) Гуманизированные моноклональные антитела к сеа с созревшей аффинностью
RU2017123549A (ru) Антитела, нацеленные на антиген созревания в-клеток, и способы их применения
JP2014528695A5 (enExample)
JP2017114866A5 (enExample)
JP2018502561A5 (enExample)
RU2020120613A (ru) Антитела, нацеленные на рецептор, связанный с g-белками, и способы их применения
JP2017205118A5 (enExample)
JP2015505665A5 (enExample)
JP2018532766A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2012010714A5 (enExample)
JP2014158485A5 (enExample)
JP2016516400A5 (enExample)
IL261666B1 (en) Binding proteins and methods of use thereof
JP2015530971A5 (enExample)
JP2014503178A5 (enExample)
JP2018505681A5 (enExample)
JP2010526028A5 (enExample)
HRP20250850T1 (hr) Antitijela protiv claudina 18.2 korisna u dijagnozi raka
JP2021500916A5 (enExample)